PRESENT VIEWS OF THE PATHOGENESIS OF OVERACTIVE BLADDER


Cite item

Full Text

Abstract

According to the data of large-scale epidemiological surveys conducted in European countries and the USA, the prevalence of overactive bladder (HB) averages 16-17%. The paper gives the main hypothesis for the causes of HB: an autonomous urinary bladder hypothesis, a myogenic hypothesis, and a neurogenic hypothesis. All three theories envisage that nervous degeneration is a common mechanism responsible for the development of HB, which points to the most important role of the nervous system in controlling the accumulating function of the bladder. This is confirmed by the data of recent studies, which suggest that there is an association between the symptoms of HB and the urinary level of nerve growth factor and its quantitative change during therapy with antimuscarinic agents and botulinum toxin A.

About the authors

I A APOLIKhINA

. M. Sechenov Moscow Medical Academy; 2 Research Institute of Urology

. M. Sechenov Moscow Medical Academy; 2 Research Institute of Urology

S Z MUSLIMOVA

Research Institute of Urology

Research Institute of Urology

F N MAKhMEDZhANOVA

3Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of theRussian Federation, Moscow

3Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of theRussian Federation, Moscow

I A Apolikhina

. M. Sechenov Moscow Medical Academy

. M. Sechenov Moscow Medical Academy

S Z Muslimova

Research Institute of Urology

Research Institute of Urology

F N Makhmedzhanova

3Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of theRussian Federation, Moscow

3Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of theRussian Federation, Moscow

References

  1. Аляев Ю.Г., Григорян В.А., Гаджиева З.К. Расстройства мочеиспускания. М., 2006.
  2. Кулаков В.И., Лопатина Т.В., Аполихина И.А. и др. Гиперактивный мочевой пузырь и императивное недержание мочи у женщин: Учебное пособие. - М., 2005.
  3. Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь // Consilium medicum. -2003. - Том 5, № 7. - С. 405-411.
  4. Пушкарь Д.Ю., Щавелева О.Б. Гиперактивный мочевой пузырь: эпидемиология, диагностика, сравнительная оценка медикаментозной терапии // Фарматека. - 2004. - №16. - С. 26-29.
  5. Урологическая гинекология: Практическое руководство для врачей / Под ред. Ю.В. Цвелева, С.Б. Петрова. - СПб, 2006.
  6. Abrams P., Wein, A. Overactive bladder (letter reply) // Urology. - 1998. - Vol. 51. - P. 1062.
  7. Garely A D., Lucente V., Vapnek et al. Solifenacin for Overactive Bladderwith Incontinence: Symptom Bother and Health-Related Quality of Life Outcomes. // Ann. Pharmacother. - 2007. - Vol. 41. - P. 391-398.
  8. Hashim H., Abrams. P. Is the Bladder a Reliable Witness for Predicting Detrusor Overactivity? // J. Urol. (Baltimore) - 2006. - Vol. 175.-P. 191-195.
  9. Irwin D., Milsom I., Kopp Z. et al. Overactive bladder symptom prevalence and health-care -seeking behaviour among men in 6 European countries// Eur. Urol. - 2005. -Vol. 4., № 3. - P. 60.
  10. Liu Hsin-Tzu, Chancellor M.B., Kuo Hann-Chorng. Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection // Eur. Urol. - 2009. - Vol. 56. - P. 700-707.
  11. Liu Hsin-Tzu, Chancellor M. B., Kuo Hann-Chorng. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. // Br.J. Urol. Int. -2009. - Vol. 103. - Р. 1668-1672.
  12. Milsom I., Abrams P., Cardoso L. et al. How widespread are the symptoms of an overactive bladder and how are they managed population-based prevalence study // Br.J. Urol. Int. - 2001. - Vol. 87. - P. 760-761.
  13. Sellers D.J., McKay N. Developments in the Pharmacotherapy of the Overactive Bladder// Cur. Opin. Urol. - 2007. - Vol. 17, № 4. - Р. 223-230.
  14. ShaabanA. Mousa, Bopaiah P. Cheppudira, Mohammed Shaqura et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain // Brain. - 2007. - Vol. 130. - Р. 502-513.
  15. Steers W.D., Kolbeck S., Creedon D., Tuttle J.B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. // J. Clin. Invest. - 1991.-Vol. 88. - Р. 1709-1715.
  16. Steers W. Overactive bladder (OAB): What we thought we knew and what we know today. // Eur. Urol. - 2002. - Vol. 1. - Р. 3-10.
  17. Stewart W., Herzog R., Wein A.J. et al. Prevalence and impact of overactive bladder in the US: Results from the NOBLE program. // Neurol. Urodyn. - 2001.-Vol. 20-Р. 403-22.
  18. Temml C., Heidler S., Ponholzer A. et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition // Eur. Urol.-2005. - Vol. 48. -Р. 622-627.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies